- Home
- CNTB
as 07-26-2024 4:00pm EST
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
| Founded: | 2012 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | 82.1M | IPO Year: | 2021 |
| Target Price: | $6.50 | AVG Volume (30 days): | 74.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.54 - $2.84 | Next Earning Date: | 09-10-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -68.56% |
Latest Connect Biopharma Holdings Limited News
CNTB Breaking Stock News: Dive into CNTB Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
GlobeNewswire
a month ago
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
Connect Biopharma Names New Chief Executive, Chair
GlobeNewswire
a month ago
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
Simply Wall St.
2 months ago
Connect Biopharma Holdings Limited's (NASDAQ:CNTB) top owners are private equity firms with 39% stake, while 22% is held by insiders
GlobeNewswire
2 months ago
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
GlobeNewswire
3 months ago
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
Newsfile
3 months ago
Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
Compare CNTB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTB Connect Biopharma Holdings Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.